Navigation Links
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Date:11/1/2008

cluding HCV, HIV and tuberculosis."

About the Phase IIa Study

Investigators in five European countries assessed the antiviral activity, safety, and pharmacokinetics of two once-daily regimens of TMC435 (25 mg or 75 mg TMC435 versus placebo) in fifty HCV genotype 1 treatment-naive patients in an ongoing double-blind, placebo-controlled phase IIa trial. Patients were randomized to receive either seven days of monotherapy with TMC435 or placebo followed by 21 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a (180 mcg once weekly) and RBV (1000-1200 mg daily); or, 28 days of triple therapy with TMC435 or placebo, plus PegIFNalpha-2a and RBV. After day 28, patients continue on PegIFNalpha-2a/RBV alone for a total of 24 or 48 weeks at the discretion of the investigator.

TMC435 data from other studies will also be presented at the AASLD Liver Meeting.

About HCV

According to the Centers for Disease Control and Prevention (CDC), about 3.2 million people in the United States are infected with chronic HCV and 19,000 people are newly infected each year.(4) Chronic infection with HCV can lead to cirrhosis and liver cancer, and is the most common cause of liver transplant in the United States.(4,5)

About Tibotec BVBA

Tibotec BVBA is a global pharmaceutical and research development company. The company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, Pa. and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.

Forward Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could var
'/>"/>

SOURCE Tibotec BVBA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... MYL ) today announced that its subsidiary Matrix Laboratories ... Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... mg, the generic version of Pfizer,s Neurontin ® Capsules ... Gabapentin Capsules had U.S. sales of approximately $300 million ...
... 2011 PAREXEL International Corporation (Nasdaq: ... the Raymond James Investors Conference in Orlando, FL.  James Winschel, ... a presentation on PAREXEL at 2:50 p.m.  ET on Monday, ... presentation will be available through the "Investors" section ...
Cached Medicine Technology:PAREXEL International to Present at Raymond James Investors Conference 2
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... ... 31, 2015 , ... Facebook, Twitter, Linkedin and blogs are ... media profiles to better connect with the public. The agency website at ... insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ways ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... Oct. 29 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... skilled nursing,facilities in Texas and California for an ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Previously leased facilities now owned, ...
... Respectively, MEXICO CITY, Oct. 28 , Financial ... millions of Mexican pesos,as of December 31, 2007 while ... current Mexican pesos. Comparisons are made with the same,period ... to rounding,practices. "bp" stands for basis points), ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
... Oct. 28 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... its third quarter 2008,financial results following the market ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Conference Call, Ensign ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... announced that it will release,financial results for the ... close on Monday, November 3, 2008. The Company ... November 3, 2008 at 5:00 p.m.,Eastern Time (2:00 ...
... Va., Oct. 28 Professional Healthcare,Resources, Inc., one ... based in the Washington, DC metropolitan area, is ... the 2008 Homecare Elite. The,selection was made by ... healthcare information agency and Decision Health(TM), a Rockville,MD ...
Cached Medicine News:Health News:The Ensign Group, Inc. Acquires Four Skilled Nursing Facilities 2Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 2Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 3Health News:Grupo Casa Saba Quarterly Earnings Report 3Q08 4Health News:The Ensign Group Schedules 2008 Third Quarter Earnings Call for Friday, October 31, 2008 2Health News:ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 2Health News:Professional Healthcare Ranked Among the Top 25 Percent of Home Health Care Providers in the Country for 2008 3
The Vision Premier software features advanced,capabilities, including automatic categorization,of beats, tachogram review and full-disclosure,viewing, providing the tools needed for even,the ...
The Deltec Cozmo® insulin pump is small, about the size of a cell phone, and only weighs 3.3 ounces (w/ battery and full cartridge). Its ergonomic design fits comfortably in the palm of your han...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... was designed specifically to meet the varying needs ... a simple to use, compact, dual application system ... field of light based hair removal. SpaTouch works ... safe for use on nearly all face and ...
Medicine Products: